Literature DB >> 2713962

Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?

J Cassidy1, D J Kerr, A Setanoians, D S Zaharko, S B Kaye.   

Abstract

We investigated the differences in plasma protein binding of flavone acetic acid (FAA) in mice and men in an attempt to explain the inter-species differences in response. In vitro data indicate both qualitative and quantitative differences in FAA protein binding: approximately 80% is bound in humans, with two different types of binding site identified; in mice, 70% is bound and only one binding site could be described. Protein binding is dose-dependent in both species. Plasma samples from 20 patients receiving FAA showed that most achieved levels that would be active in mice. We conclude that these differences in protein binding are insufficient to explain totally the observed differences in response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713962     DOI: 10.1007/BF00435845

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Advanced modeling and identification techniques for metabolic processes.

Authors:  G Belforte; B Bona; M Milanese
Journal:  Crit Rev Biomed Eng       Date:  1984

2.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

3.  Phase I and pharmacokinetic study of flavone acetic acid.

Authors:  D J Kerr; S B Kaye; J Cassidy; C Bradley; E M Rankin; L Adams; A Setanoians; T Young; G Forrest; M Soukop
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

4.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.

Authors:  J Plowman; V L Narayanan; D Dykes; E Szarvasi; P Briet; O C Yoder; K D Paull
Journal:  Cancer Treat Rep       Date:  1986-05

6.  Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).

Authors:  M C Bibby; J A Double; R M Phillips; P M Loadman
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  6 in total
  4 in total

1.  Flavone acetic acid and plasma protein binding.

Authors:  J Brodfuehrer; F Valeriote; K Chan; L Heilbrun; T Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma.

Authors:  S B Kaye; M Clavel; P Dodion; S Monfardini; W ten Bokkel-Huinink; D T Wagener; S Gundersen; G Stoter; J Smith; J Renard
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

4.  Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.

Authors:  M V Relling; R R Evans; S Groom; W R Crom; C B Pratt
Journal:  J Pharmacokinet Biopharm       Date:  1993-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.